LDS/Medical Tests/Familial Adenomatous Polyposis (APC) Gene Mutation Analysis, Sequencing

Familial Adenomatous Polyposis (APC) Gene Mutation Analysis, Sequencing

Colorectal cancer is one of the most common malignancies in the U.S. It is the third most common cancer worldwide and the fourth most common cause of cancer deaths. The etiology is multifactorial and includes both genetic and environmental factors. Approximately 5% of all colorectal cancers harbor a germline mutation that predisposes the individuals to develop cancer. Germline mutations involving APC and MUTYH (MYH) genes constitute a majority of inherited colorectal cancer syndromes.

Germline APC mutations are identified in familial adenomatous polyposis (FAP) syndrome, Gardner's syndrome, Turcot's syndrome and attenuated adenomatous polyposis coli syndrome, all of which predispose the patients to develop colorectal cancer in their early life. FAP syndrome is clinically suspected when hundreds to thousands of adenomatous polyps are endoscopically and/or colonoscopically identified in a young individual. These adenomatous polyps invariably progress to invasive adenocarcinoma. Concomitant presence of desmoid tumors, hepatobiliary and pancreatic neoplasms, osteomas of mandible, epidermoid cysts and/or other skin lesions raises a suspicion of Gardner’s syndrome.

Turcot's syndrome is associated with gastrointestinal polyps and certain brain tumors (medulloblastoma and glioblastoma multiforme). Attenuated FAP syndrome is a rare hypomorphic manifestation of FAP characterized by fewer polyps than the classical FAP syndrome. Lifetime risk of developing colorectal cancer in individuals with germline FAP mutations approaches 100% and warrants prophylactic total colectomy in early adulthood. Most of the documented APC mutations (>95%) are either frameshift mutations or non-sense mutations. Large deletions and copy number variations form a minority of the APC mutations.

MUTYH-associated polyposis (MAP) clinically mimics FAP syndrome but differs in the genetics and familial inheritance patterns. MAP is characterized by a homozygous state of germline MUTYH mutation and shows an autosomal recessive pattern of inheritance. Clinical implications and the risk of colorectal cancer in individuals with monoallelic mutations (heterozygotes) are not well established. Documented MUTYH mutations include two point mutations, Y165C and G382D.

  • To confirm the diagnosis of Familial Adenomatous Polyposis
  • As an aid in diagnosis of Gardner’s syndrome
  • As an aid in diagnosis of Turcot’s syndrome, attenuated FAP or MAP in patients with a strong family history or clinical features of the same
  • To identify mutations in asymptomatic family members of an individual with APC or MUTYH mutation for close clinical surveillance and prophylactic surgery
  • Disease management and therapy treatment regimen

Identification of a deleterious APC mutation in one of the alleles almost always implies FAP or variant FAP syndromes, given the high penetrance of the disease.

  • Laboratory diagnosis of MAP can be made if deleterious mutations are identified on both the alleles of MUTYH.
  • A negative result does not always rule out FAP, variant FAP syndromes or MAP, due to a possibility of undetectable mutations in the specific gene(s) analyzed or a mutation in another gene.
  • An uncertain result means that a mutation was detected whose phenotypic association and clinical implication are not well understood/established. Clinical presentation, pathologic examination and patient's family history should guide diagnosis and clinical management of the patient.
Polymerase Chain Reaction (PCR) and Sequencing. Genomic DNA is isolated from the patient’s sample and genes of interest (APC and MUTYH) are amplified by PCR. Amplicons are analyzed by bi-directional targeted sequence analysis by traditional (Sanger's) sequencing. Next Generation Sequencing (NGS).

Whole blood or Buccal swabs. 

Whole blood in a lavender top (EDTA) tube.
Buccal swabs with appropriate transport media.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
  • Frozen: 30 days

If APC mutations are not detected and clinical suspicion remains high, deep intronic or regulatory region mutations can be considered. If MUTYH mutations are not detected and clinical suspicion remains high, mutations other than Y165C and G382D should be considered. Other tumor markers: KRAS, NRAS, Microsatellite Instability (MSI), p53, Intestinal biopsy (polyps).

1-2 weeks. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login